64cu-sar-bispsma
Recombinant proteinexperimentalImaging agent
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jul 13, 2021 (NCT04839367)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06970847 | Phase 3 | May 16, 2025 | Clarity Pharmaceuticals Ltd |
| NCT06907641 | Phase 2 | Nov 21, 2024 | Clarity Pharmaceuticals Ltd, University of New South Wales |
| NCT06056830 | Phase 3 | Nov 30, 2023 | Clarity Pharmaceuticals Ltd |
| NCT05249127 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2022 | Clarity Pharmaceuticals Ltd |
| NCT04868604 | Phase 1/Phase 2 (Phase 2) | Aug 11, 2021 | Clarity Pharmaceuticals Ltd |
| NCT04839367 | Phase 1 | Jul 13, 2021 | Clarity Pharmaceuticals Ltd |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarity Pharmaceuticals Ltd | For profit | 6 | 5 | 3 | 2021 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1